Menu
Search Clinical Trials
Back to Search Results
Study Complete
Astellas Study ID
0819-CL-0201

A Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients with Fibromyalgia

Astellas Study ID
0819-CL-0201
Clinicaltrials.gov ID
NCT03056690
EUCTIS ID
N/A
EudraCT ID
N/A
jRCT ID
N/A
CN CDE ID
N/A
Get more information

Study summary

This study assessed analgesic efficacy of ASP0819 relative to placebo as well as the safety and tolerability.

This study assessed treatment differences in physical function as well as the improvements in overall subject status (e.g., fibromyalgia symptoms and global functioning) of ASP0819 relative to placebo.

Additional Study Details

Phase
Phase 2
Product
ASP0819
Product
ASP0819
Placebo
Type
Interventional
Masking
Double (Participant, Investigator)
Enrollment number
186
Show Additional Study Details

Study documents

Scientific Results Summary
Available Language(s): English
Download Document(s)
Plain Language Summary
Available Language(s): English
Download Document(s)
Protocol
Available Language(s): English
Download Document(s)
Statistical Analysis Plan (SAP)
Available Language(s): English
Download Document(s)

Get more information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients with Fibromyalgia? Contact us by filling out your information to the right and we’ll respond to you.

  • A caregiver
  • A healthcare provider
  • A parent
  • A patient
  • A patient advocate
  • Algeria
  • Argentina
  • Armenia
  • Australia
  • Austria
  • Belarus
  • Belgium
  • Bosnia And Herzegovina
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • China
  • Colombia
  • Croatia
  • Czech Republic
  • Denmark
  • Dominican Republic
  • Egypt
  • Estonia
  • Finland
  • Former Serbia and Montenegro
  • France
  • Georgia
  • Germany
  • Greece
  • Guatemala
  • Hong Kong
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Ireland
  • Israel
  • Italy
  • Japan
  • Jordan
  • Kazakhstan
  • Latvia
  • Lebanon
  • Lithuania
  • Macedonia
  • Malaysia
  • Mexico
  • Montenegro
  • Morocco
  • Netherlands
  • New Zealand
  • Norway
  • Panama
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Puerto Rico
  • Republic of Korea
  • Republic of Moldova
  • Romania
  • Russian Federation
  • Saudi Arabia
  • Serbia
  • Singapore
  • Slovakia
  • Slovenia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan, Province of China
  • Thailand
  • Turkey
  • Ukraine
  • United Kingdom
  • United States
  • Vietnam

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

    Locations

    Contact Us
    Contact Us
    Completed
    Site US10055 - Central Kentucky Research Asc
    Lexington, KY, United States, 40509
    Contact Us
    Completed
    Site US10059 - Hillcrest Clinical
    Oklahoma City, OK, United States, 73119
    Contact Us
    Completed
    Site US10006 - Columbus Regional Research Ins
    Columbus, GA, United States, 31904
    Contact Us
    Completed
    Site US10018 - Altea Research Institute
    Las Vegas, NV, United States, 89102
    Contact Us
    Completed
    Site US10005 - Charlottesville Med Research
    Charlottesville, VA, United States, 22911
    Contact Us
    Completed
    Site US10031 - Wake Research Associates
    Raleigh, NC, United States, 27612
    Contact Us
    Completed
    Site US10012 - Palm Beach Research Center
    West Palm Beach, FL, United States, 33409
    Contact Us
    Completed
    Site US10003 - Artemis Inst For Clin Research
    San Diego, CA, United States, 92103
    Contact Us
    Completed
    Site US10037 - Dept of Psychiatry and Neuro University of Cincinnati
    Cincinnati, OH, United States, 45219
    Contact Us
    Completed
    Site US10019 - Lillestol Research LLC
    Fargo, ND, United States, 58103
    Contact Us
    Completed
    Site US10039 - Superior Research LLC
    Sacramento, CA, United States, 95831
    Contact Us
    Completed
    Site US10028 - Renstar Medical Research
    Ocala, FL, United States, 34471
    Contact Us
    Completed
    Site US10038 - Heartland Research Associates
    Wichita, KS, United States, 67205
    Contact Us
    Completed
    Site US10024 - Compass Research LLC
    Orlando, FL, United States, 32806
    Contact Us
    Completed
    Site US10010 - Upstate Clinical Research Asc
    Williamsville, NY, United States, 14221
    Contact Us
    Completed
    Site US10032 - Peters Medical Research
    High Point, NC, United States, 27262
    Contact Us
    Completed
    Site US10023 - Oregon Ctr for Clinical Invest
    Salem, OR, United States, 97301
    Contact Us
    Completed
    Site US10045 - TriWest Research Associates
    El Cajon, CA, United States, 92020
    Contact Us
    Completed
    Site US10025 - Achieve Clinical Research, LLC
    Birmingham, AL, United States, 35216
    Contact Us
    Completed
    Site US10013 - Bateman Horne Center
    Salt Lake City, UT, United States, 84102
    Contact Us
    Completed
    Site US10027 - BTC of New Bedford LLC
    New Bedford, MA, United States, 02740
    Contact Us
    Completed
    Site US10056 - Atlanta Ctr for Med Research
    Atlanta, GA, United States, 30331
    Contact Us
    Completed
    Site US10043 - Oregon Ctr for Clinical Invest
    Portland, OR, United States, 97214
    Contact Us
    Completed
    Site US10048 - Diablo Clinical Research Inc
    Walnut Creek, CA, United States, 94598
    Contact Us
    Withdrawn
    Site US10035 - McIlwain Medical Research
    Tampa, FL, United States, 33614
    Contact Us
    Trial info
    Follow Trial
    Age
    18 - 80 years
    Diamond icon
    Condition
  • Fibromyalgia
    • Gender icon
    Sex
    Female & Male
    Calendar icon
    Trial Dates
    Mar 2017 - Feb 2018
    Additional Study Details
    Inclusion Criteria
    • Subject has a body mass index (BMI) ≤ 45 kg/m2.
    • Female subject must either:
      • Be of nonchildbearing potential: postmenopausal (defined as at least 1 year without any menses) prior to Screening, or documented surgically sterile (e.g., hysterectomy, bilateral salpingectomy, bilateral oophorectomy).
      • Or, if of childbearing potential: agree not to try to become pregnant during the study and for 28 days after the final study drug administration, have a negative blood pregnancy test at Screening and negative urine test on Day 1, and if heterosexually active, agree to consistently use 1 form of highly effective birth control starting at Screening and throughout the study period and for 28 days after the final study drug administration.
    • Female subject must agree not to breastfeed at Screening and throughout the study period, and for 28 days after the final study drug administration.
    • Female subject must not donate ova starting at Screening, throughout the study period, and for 28 days after the final study drug administration
    • Male subject must not donate sperm starting at Screening and throughout the study period, and for 28 days after the final study drug administration.
    • Male subject with a partner of child-bearing potential, or a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom throughout the study period and for 28 days after the final study drug administration.
    • Subject meets the American College of Rheumatology (ACR) 1990 fibromyalgia diagnostic criteria at Screening:
      • Widespread pain for at least 3 months, defined as the presence of all of the following: pain on right and left sides of the body, pain above and below the waist, and pain in the axial skeleton (cervical spine or anterior chest or thoracic spine or low back) must be present.
      • Pain in at least 11 of 18 tender point sites on digital palpation. Digital palpation should be performed with an approximate force of 4 kg.
    • Subject meets the ACR 2010 fibromyalgia diagnostic criteria at Screening:
      • Widespread pain index (WPI) ≥ 7 and Symptom severity (SS) scale score ≥ 5 or WPI 3-6 and SS scale score ≥ 9.
      • Symptoms have been present at a similar level for at least 3 months.
      • The subject does not have a disorder that would otherwise explain the pain.
    • Subject has a pain score ≥ 4 on the revised fibromyalgia impact questionnaire revised (FIQR) pain item at Screening.
    • Subject is compliant with daily pain recordings during the Baseline Diary Run-In period, as defined by the completion of a minimum of 5 of 7 daily average pain ratings and agrees to complete daily diaries throughout the duration of the study.
    • Subject has a mean daily average pain score ≥ 4 and ≤ 9 on an 11-point 0 to 10 NRS as recorded in the subject e-diary during the Baseline Diary Run-In period, and meeting pre-specified criteria for daily average pain scores.
    • Subject agrees to use only acetaminophen as rescue medication for fibromyalgia pain throughout the course of the trial (up to 1000 mg per dose and not to exceed 3000 mg/day).
    • Subject agrees not to initiate or change any non-pharmacologic interventions (including normal daily exercise routines, chiropractic care, physical therapy, psychotherapy, and massage therapy) during the course of the study. Non-pharmacologic interventions must be stable for a minimum of 30 days prior to Screening. The subject agrees to maintain usual level of activity for the duration of the study.
    • Subject is capable of completing study assessments and procedures.
    • Subject agrees not to participate in another interventional study from Screening through the End of Study (EOS) visit.
    MaximizeExclusion Criteria
    • Subject has received an investigational therapy within 28 days or 5 half-lives, whichever is longer, prior to Screening.
    • Subject has had no meaningful improvement, from 2 or more prior treatments (commercially available) for fibromyalgia (in at least 2 pharmacologic classes).
    • Subject has had known hypersensitivity or intolerance to the use of acetaminophen or associated formulation components; known hypersensitivity to the formulation components of ASP0819.
    • Subject has pain due to diabetic peripheral neuropathy, post-herpetic neuralgia, traumatic injury, prior surgery, complex regional pain syndrome, or other source of pain that would confound or interfere with the assessment of the subject’s fibromyalgia pain or require excluded therapies during the subject’s study participation.
    • Subject has infectious or inflammatory arthritis (e.g., rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and gout), autoimmune disease (e.g., systemic lupus erythematosus), or other widespread rheumatic disease other than fibromyalgia.
    • Subject has a current, untreated moderate or severe major depressive disorder as assessed by the Mini-International Neuropsychiatric Interview (M.I.N.I.). Subject with current, treated major depressive disorder can be included provided that it is without clinically significant changes in symptoms while on the same dose of a protocol allowed antidepressant for greater than 60 days prior to Screening.
    • Subject has initiated any non-pharmacologic interventions for the treatment of fibromyalgia or depression within 30 days prior to Screening or during the Screening period.
    • Subject has a history of any psychotic and/or bipolar disorder as assessed by the M.I.N.I.
    • Subject has a Hospital Anxiety and Depression Scale (HADS) score > 14 on the Depression subscale at Screening or at the time of Visit 3 (Randomization).
    • Subject has a history of suicide attempt or suicidal behavior within the last 12 months, or has suicidal ideation within the last 12 months (a response of “yes” to questions 4 or 5 on the suicidal ideation portion of the Columbia-Suicide Severity Rating Scale (C-SSRS)), or who is at significant risk to commit suicide at the time of Visit 3 (Randomization).
    • Subject has clinically significant abnormalities in clinical chemistry, hematology, or urinalysis, or a serum creatinine > 1.5 times the Upper limit of normal (ULN) at Screening. These assessments may be repeated once, after a reasonable time period (but within the Screening period).
    • Subject has aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 1.5 times the upper limit of the reference range at Screening. These assessments may be repeated once, after a reasonable time period (but within the Screening period).
    • Subject has a positive test for hepatitis B surface antigen (HBsAg), hepatitis A virus antibodies (immunoglobulin M) (anti-HAV [IgM]) or hepatitis C virus antibodies (anti-HCV) at Screening or has history of a positive test for human immunodeficiency virus type 1(HIV-1) and/or type 2 (HIV-2).
    • Subject has a resting systolic blood pressure (SBP) > 180 mmHg or < 90 mmHg, and/or a sitting diastolic blood pressure (DBP) > 100 mmHg at Screening. These assessments may be repeated once, after a reasonable time period (but within the Screening period).
    • Subject has a clinically significant abnormality on 12-lead Electrocardiogram (ECG) at Screening or Visit 3 (Randomization). If the ECG is abnormal, an additional ECG can be carried out. If this also gives an abnormal result, the subject must be excluded.
    • Subject has a history of myocardial infarction (within 6 months of Screening), unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsade de pointes, structural heart disease or a family history of Long time from electrocardiogram Q wave to the end of the T wave (QT) Syndrome.
    • Subject has evidence of any clinically significant, uncontrolled cardiovascular, gastrointestinal, endocrinologic (low thyroid stimulating hormone [TSH], but euthyroid is allowed), hematologic, hepatic, immunologic, infectious, metabolic, urologic, pulmonary (including obstructive sleep apnea not controlled by a Continuous positive airway pressure (CPAP) device) neurologic, dermatologic, psychiatric, renal and/or other major disease (exclusive of fibromyalgia).
    • Subject has planned surgery during the study participation.
    • Subject has an active malignancy or a history of malignancy (except for treated nonmelanoma skin cancer) within 5 years of Screening.
    • Subject has a positive drug or alcohol test at Screening, Baseline Diary Run-In or prior to Randomization. However, a positive test for tetrahydrocannabinol (THC) and/or opioids is allowed at the Screening visit, but must be confirmed negative prior to Baseline Diary Run-In and Randomization.
    • Subject has a current or recent (within 12 months of Screening) history of a substance use disorder including cannabinoid and/or alcohol abuse disorder. Subject has used opioids for pain for more than 4 days during the week preceding the Screening visit.
    • Subject is currently using protocol specified prohibited medications and is unable to wash-out.
    • Subject has filed or is awaiting judgment on a disability claim or has any pending worker’s compensation litigation or related monetary settlements.
    • Subject is an employee of the Astellas Group, the Contract Research Organization (CRO) involved, or the investigator site personnel directly affiliated with this study and/or their immediate families (spouse, parent, child, or sibling, whether biological or legally adopted).

    Frequently Asked Questions

    Are clinical trials only for people with advanced cancer?

    While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

    Will I have to stop my current treatment to participate in a clinical trial?

    Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

    Should I be worried about getting a placebo?

    In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

    Do I need a referral from my doctor to take part in a study?

    Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

    Explore More

    1

    What are clinical trials?

    Find a Trial
    2

    Why are Clinical Trials Important?

    Learn More
    3

    Why Participate in a Clinical Trial?

    Discover More